Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
26
BOLT Quote, Financials, Valuation and Earnings
Last price:
$5.80
Seasonality move
:
-23.31%
Day range:
$5.70 - $5.87
52-week range:
$5.20 - $15.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.14x
P/B ratio:
0.24x
Volume:
3.3K
Avg. volume:
24.3K
1-year change:
-61.2%
Market cap:
$11M
Revenue:
$7.7M
EPS (TTM):
-$33.40
Analysts' Opinion
-
Consensus RatingBolt Biotherapeutics has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $2.00, Bolt Biotherapeutics has an estimated upside of 596.86% from its current price of $5.74.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.00 representing 100% downside risk from its current price of $5.74.
Fair Value
-
According to the consensus of 4 analysts, Bolt Biotherapeutics has 596.86% upside to fair value with a price target of $2.00 per share.
BOLT vs. S&P 500
-
Over the past 5 trading days, Bolt Biotherapeutics has underperformed the S&P 500 by -9.72% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Bolt Biotherapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bolt Biotherapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Bolt Biotherapeutics reported revenues of $1.2M.
Earnings Growth
-
Bolt Biotherapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Bolt Biotherapeutics reported earnings per share of -$5.80.
Enterprise value:
-27.8M
EV / Invested capital:
--
Price / LTM sales:
1.14x
EV / EBIT:
--
EV / Revenue:
-3.69x
PEG ratio (5yr expected):
-0.29x
EV / Free cash flow:
0.48x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-56.37%
Net Income Margin (TTM):
-665.56%
Return On Equity:
-86.53%
Return On Invested Capital:
-86.53%
Operating Margin:
-991.41%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $6.7M | $11.3M | -- | $5.3M | $1.2M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$84.9M | -$74.9M | -$63.3M | -$17.1M | -$12.1M | |
| EBITDA | -$83.1M | -$73M | -$61.5M | -$16.6M | -$11.7M | |
| Diluted EPS | -$43.40 | -$33.20 | -$33.40 | -$5.60 | -$5.80 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $271.2M | $196.1M | $131.6M | $95.1M | $42.5M | |
| Total Assets | $324.6M | $282.8M | $206.2M | $142.9M | $85.9M | |
| Current Liabilities | $12M | $19.3M | $16.3M | $16.7M | $13.6M | |
| Total Liabilities | $21.4M | $54.4M | $48.5M | $38.7M | $39.1M | |
| Total Equity | $303.2M | $228.4M | $157.7M | $104.2M | $46.8M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$75.6M | -$62.9M | -$57.9M | -$16.8M | -$13.4M | |
| Cash From Investing | $46M | $52.3M | $61.9M | $10.2M | $14.6M | |
| Cash From Financing | -- | $253K | $108K | -- | -- | |
| Free Cash Flow | -$76.9M | -$63.1M | -$57.9M | -$16.8M | -$13.4M | |
BOLT
Sector
Market Cap
$11M
$34.4M
Price % of 52-Week High
36.8%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-61.2%
-37.36%
Beta (5-Year)
--
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$5.98
200-day SMA
Sell
Level
$9.29
Bollinger Bands (100)
Sell
Level
5.94 - 8.22
Chaikin Money Flow
Sell
Level
-1.2M
20-day SMA
Sell
Level
$5.85
Relative Strength Index (RSI14)
Sell
Level
43.75
ADX Line
Sell
Level
9.03
Williams %R
Neutral
Level
-75
50-day SMA
Sell
Level
$6.21
MACD (12, 26)
Sell
Level
-0.09
25-day Aroon Oscillator
Sell
Level
-28
On Balance Volume
Sell
Level
-961.3K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-7.4775)
Sell
CA Score
(Annual)
Level (-2.1021)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (2)
Sell
Ohlson Score
Level (4.5257)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
Stock Forecast FAQ
In the current month, BOLT has received 1 Buy ratings 3 Hold ratings, and 0 Sell ratings. The BOLT average analyst price target in the past 3 months is $2.00.
-
Where Will Bolt Biotherapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bolt Biotherapeutics share price will rise to $2.00 per share over the next 12 months.
-
What Do Analysts Say About Bolt Biotherapeutics?
Analysts are divided on their view about Bolt Biotherapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bolt Biotherapeutics is a Sell and believe this share price will drop from its current level to $1.00.
-
What Is Bolt Biotherapeutics's Price Target?
The price target for Bolt Biotherapeutics over the next 1-year time period is forecast to be $2.00 according to 4 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is BOLT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bolt Biotherapeutics is a Hold. 3 of 4 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of BOLT?
You can purchase shares of Bolt Biotherapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bolt Biotherapeutics shares.
-
What Is The Bolt Biotherapeutics Share Price Today?
Bolt Biotherapeutics was last trading at $5.80 per share. This represents the most recent stock quote for Bolt Biotherapeutics. Yesterday, Bolt Biotherapeutics closed at $5.74 per share.
-
How To Buy Bolt Biotherapeutics Stock Online?
In order to purchase Bolt Biotherapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
72
SBET alert for Jul 18
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
68
MCRI alert for Jul 18
Monarch Casino & Resort [MCRI] is up 19.81% over the past day.
Sell
41
NEGG alert for Jul 18
Newegg Commerce [NEGG] is up 17.85% over the past day.
